芒针疗法治疗脑卒中后运动与平衡障碍的多中心随机对照研究及推广应用

注册号:

Registration number:

ITMCTR2024000208

最近更新日期:

Date of Last Refreshed on:

2024-08-10

注册时间:

Date of Registration:

2024-08-10

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

芒针疗法治疗脑卒中后运动与平衡障碍的多中心随机对照研究及推广应用

Public title:

Multi-center Randomized Controlled Study and Application of Elongated Needle Therapy in the Treatment of Motor and Balance Disorders after Stroke

注册题目简写:

English Acronym:

研究课题的正式科学名称:

芒针疗法治疗脑卒中后运动与平衡障碍的多中心随机对照研究及推广应用

Scientific title:

Multi-center Randomized Controlled Study and Application of Elongated Needle Therapy in the Treatment of Motor and Balance Disorders after Stroke

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

葛逊

研究负责人:

李佩芳

Applicant:

Ge Xun

Study leader:

Li Pei Fang

申请注册联系人电话:

Applicant telephone:

18755171021

研究负责人电话:

Study leader's telephone:

13956955697

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1047723752@qq.com

研究负责人电子邮件:

Study leader's E-mail:

lipf67@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

安徽省合肥市庐阳区安徽省针灸医院脑病二科

研究负责人通讯地址:

安徽省合肥市庐阳区安徽省针灸医院脑病二科

Applicant address:

Department of Encephalopathy, Anhui Acupuncture and Moxibustion Hospital, Hefei City, Anhui Provinc

Study leader's address:

Department of Encephalopathy, Anhui Acupuncture and Moxibustion Hospital, Hefei City, Anhui Provinc

申请注册联系人邮政编码:

Applicant postcode:

230000

研究负责人邮政编码:

Study leader's postcode:

230000

申请人所在单位:

安徽中医药大学第二附属医院

Applicant's institution:

The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2023-zj-29

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

安徽中医药大学第二附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2023/11/30 0:00:00

伦理委员会联系人:

束樱子

Contact Name of the ethic committee:

Shu Ying Zi

伦理委员会联系地址:

安徽省合肥市庐阳区安徽省针灸医院

Contact Address of the ethic committee:

Anhui Acupuncture and Moxibustion Hospital, Luyang District, Hefei City, Anhui Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

13866789372

伦理委员会联系人邮箱:

Contact email of the ethic committee:

ahzjyykjk@163.com

研究实施负责(组长)单位:

安徽中医药大学第二附属医院

Primary sponsor:

The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

安徽省合肥市庐阳区安徽省针灸医院

Primary sponsor's address:

Anhui Acupuncture and Moxibustion Hospital, Luyang District, Hefei City, Anhui Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

合肥市

Country:

China

Province:

Anhui

City:

Hefei City

单位(医院):

安徽中医药大学第二附属医院

具体地址:

安徽省合肥市庐阳区寿春路300号安徽省针灸医院

Institution
hospital:

The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine

Address:

Anhui acupuncture hospital, No.300, Shouchun road, Luyang district, Hefei City, Anhui province

经费或物资来源:

安徽省科学技术厅

Source(s) of funding:

Department of Science and Technology of Anhui Province

研究疾病:

脑卒中

研究疾病代码:

Target disease:

Stroke

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

现代医学针对神经修复的治疗手段非常有限,效果也不太理想。我们前期在治疗中风后相关功能障碍的临床实践中不断优化治疗方案,发现芒针透刺脑卒中后拮抗肌、躯干肌的治疗方案,可以较好地改善患者运动及平衡功能,同时也进行了临床报道。因此,开展芒针疗法治疗脑卒中后运动与平衡功能障碍的临床随机对照研究,为芒针特色针法的临床推广应用提供高级别循证医学证据具有重要的理论与实际意义。

Objectives of Study:

Modern medical treatment for nerve repair is very limited, and the effect is not ideal. We're pretreating a stroke. In the clinical practice of post-stroke related dysfunction, the treatment plan was constantly optimized, and it was found that the elongated needle penetrated the antagonistic muscles and trunk muscles after stroke. The treatment program can better improve the motor and balance function of patients, and also carried out clinical reports. Therefore, carry out The clinical randomized controlled study of elongated needle therapy in the treatment of motor and balance dysfunction after stroke is a clinical study of elongated needle therapy. It is of great theoretical and practical significance to provide high-level evidence-based medical evidence for popularization and application.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

① 符合脑卒中的中西医诊断标准,并经 CT 或 MRI 明确诊断的患者; ② 年龄大于 18 岁,小于 75 岁的脑病科住院患者; ③ 符合诊断标准,病程在 1 年以内者; ④ 有平衡功能障碍者,Berg 平衡功能评定量表评分<40 分; ⑤ 有运动功能障碍者,徒手肌力检查<5 级;修订的 Ashworth 痉挛量表≥Ⅰ级为硬瘫期,< Ⅰ级为软瘫期。 ⑥ 自愿参加本研究项目者。

Inclusion criteria

① Patients who met the diagnostic criteria of traditional Chinese and Western medicine for stroke and were definitely diagnosed by CT or MRI; ② Patients in the department of encephalopathy who were older than 18 years and younger than 75 years; ③ Patients who met the diagnostic criteria and had a course of disease within 1 year; ④ Patients with balance dysfunction were assessed with Berg Balance Function Rating Scale. 40 minutes; ⑤ Bare-handed muscle strength examination for patients with motor dysfunction Grade 5; modified Ashworth spasticity scale ≥ Grade I is the stage of hard paralysis. Grade I was flaccid paralysis. ⑥ Those who volunteered to participate in the research project.

排除标准:

① 并发心肌梗塞或合并严重肝肾功能障碍、前庭功能或小脑功能障碍等患者; ② 妊娠期或哺乳期妇女; ③ 病程在一年以上者; ④ 最近 1 月内参加过其他药物临床研究者; ⑤ 其余原因导致的肢体严重损伤者、昏迷及不配合治疗者。

Exclusion criteria:

① Patients with myocardial infarction or severe hepatic and renal dysfunction, vestibular dysfunction or cerebellar dysfunction; ② Pregnant or lactating women; ③ The course of disease was more than one year; ④ Participated in clinical research of other drugs within the last month; ⑤ Patients with severe limb injury, coma and uncooperative treatment caused by other reasons.

研究实施时间:

Study execute time:

From 2023-09-14

To      2026-09-13

征募观察对象时间:

Recruiting time:

From 2023-12-01

To      2025-09-14

干预措施:

Interventions:

组别:

对照组

样本量:

118

Group:

Control group

Sample size:

干预措施:

普通针刺

干预措施代码:

Intervention:

Common needling

Intervention code:

组别:

观察组

样本量:

118

Group:

Observation group

Sample size:

干预措施:

芒针

干预措施代码:

Intervention:

Elongated needle

Intervention code:

样本总量 Total sample size : 236

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

安徽

市(区县):

亳州市

Country:

China

Province:

Anhui

City:

Bozhou City

单位(医院):

亳州市人民医院

单位级别:

三甲

Institution/hospital:

Bozhou People's Hospital

Level of the institution:

Grade III A

国家:

中国

省(直辖市):

安徽

市(区县):

安庆市

Country:

China

Province:

Anhui

City:

Anqing City

单位(医院):

安庆市第一人民医院

单位级别:

三甲

Institution/hospital:

Anqing First People's Hospital

Level of the institution:

Grade III A

国家:

中国

省(直辖市):

安徽省

市(区县):

合肥市

Country:

China

Province:

Anhui

City:

Hefei City

单位(医院):

安徽中医药大学第二附属医院

单位级别:

三甲

Institution/hospital:

The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine

Level of the institution:

Grade III A

国家:

中国

省(直辖市):

安徽

市(区县):

宣城市

Country:

China

Province:

Anhui

City:

Xuancheng City

单位(医院):

郎溪县中医院

单位级别:

二甲

Institution/hospital:

Langxi County Hospital of Traditional Chinese Medicine

Level of the institution:

Grade II A

国家:

中国

省(直辖市):

安徽

市(区县):

滁州市

Country:

China

Province:

Anhui

City:

Chuzhou City

单位(医院):

滁州市中西医结合医院

单位级别:

三甲

Institution/hospital:

Chuzhou Hospital of Integrated Traditional Chinese and Western Medicine

Level of the institution:

Grade III A

国家:

中国

省(直辖市):

安徽

市(区县):

安庆市

Country:

China

Province:

Anhui

City:

Anqing City

单位(医院):

岳西县中医院

单位级别:

三乙

Institution/hospital:

Yuexi County Hospital of Traditional Chinese Medicine

Level of the institution:

Grade III B

测量指标:

Outcomes:

指标中文名:

修订的 Ashworth 痉挛量表

指标类型:

主要指标

Outcome:

Revised Ashworth Scale for Spasticity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应发生率

指标类型:

次要指标

Outcome:

Incidence of adverse reactions

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Fugl-Meyer 功能评定量表

指标类型:

主要指标

Outcome:

Fugl-Meyer Functional Rating Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Berg 平衡量表

指标类型:

主要指标

Outcome:

Berg balance scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

FIM 量表

指标类型:

主要指标

Outcome:

FIM scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Barthel 指数评分

指标类型:

主要指标

Outcome:

Barthel index score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候积分变化

指标类型:

主要指标

Outcome:

Changes of TCM syndrome integral

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者的临床症状体征

指标类型:

次要指标

Outcome:

Clinical symptoms and signs of the patient

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由成都明科临床医学研究有限公司专业人员应用计算机函数产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

The professionals of Chengdu Mingke Clinical Medical Research Co., Ltd. used computer functions to generate random sequences.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

CIMS云平台 https://trial.cims-medtech.com/CIMS_V5/?uc=C109

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

CIMS cloud platform https://trial.cims-medtech.com/CIMS_V5/?uc=C109

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统,CIMS云平台:基于互联网的EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Acquisition and Management System, CIMS Cloud Platform: Internet-based EDC.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统